Diaprost
Business Services · Sweden · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Scheelevägen Medicon Village 2, Lund, Sw...Phone Number
+46 709224140Website
www.diaprost.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Diaprost
Diaprost is a biotechnology company focused on the research and development of innovative diagnostics and therapeutics specifically for prostate cancer. The company aims to revolutionize personalized medicine through its proprietary antibody platform, enhancing the reliability of prostate cancer detection and enabling targeted treatments. Diaprost collaborates with leading international experts and institutions, including Memorial Sloan Kettering Cancer Center, to advance its scientific initiatives. Founded in 2005, Diaprost is committed to fighting prostate cancer through science-driven approaches and strategic partnerships.Explore more
Popular SearchesDiaprost AbSIC Code 87,873NAICS Code 54,541Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Diaprost your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Diaprost, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Diaprost recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Diaprost
Check if Diaprost has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Diaprost has new funding data
Click to see if Diaprost had a recent Job posting/layoffs
Check out if Diaprost is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Diaprost launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Diaprost is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Diaprost is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Diaprost.
Diaprost Tech Stack
A closer look at the technologies used by Diaprost
See more technologies
Diaprost News & Media
Diaprost Announces Promising New Study for Patients with Metastatic PCa
Diaprost announced today a publication in the journal of Clinical Cancer Research on PSA-targeted Alpha-, Beta- and Positron Emitting Immuno-Theranostics in Murine Prostate Cancer Models and Non-Human Primates. The extensive preclinical study was conducted at Memorial Sloan Kettering Cancer Center (MSK) on Diaprost’s propriety antibody (hu5A10) targeting PSA. This rigorous preclinical evaluation of radiolabeled hu5A10-based compounds in prostate cancer (PCa) mouse models and non-human primates,Diaprost AB Acquires Rights to use of PSA Antibodies from Leading New York Cancer Center
Diaprost announced today that it has signed an exclusive license agreement with Memorial Sloan Kettering Cancer Center for IP related to the use of PSA antibodies for therapeutic and diagnostic purposes for prostate cancer. Diaprost is a private pharmaceutical research and development company based in Lund, Sweden and whose principle asset is h5A10, targeting PSA, a validated clinical biomarker. The h5A10 antibody combined with the appropriate payload offers the potential for highly specific theDiaprost Announces Exercise of Option Under the Terms of its Research and Option Agreement With a Leading Pharmaceutical Company
Diaprost entered into an exclusive Research and Option Agreement with a Top 10 Pharmaceutical company strategic partner in October 2017. Diaprost now announces that its strategic partner has exercised its option to acquire rights to its h11B6 antibody.Diaprost Announces Exercise of Option Under the Terms of its Research and Option Agreement With a Leading Pharmaceutical Company
LUND, Sweden, Jan. 21, 2020 /PRNewswire/ -- Diaprost entered into an exclusive Research and Option Agreement with a Top 10 Pharmaceutical company strategic partner in October 2017. Diaprost now announces that its strategic partner has exercised its option to acquire rights to its h11B6...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Diaprost
Sign Up For FreeTo access detailed company insights
Diaprost is a biotechnology company focused on the research and development of innovative diagnostics and therapeutics specifically for prostate cancer. The company aims to revolutionize personalized medicine through its proprietary antibody platform, enhancing the reliability of prostate cancer detection and enabling targeted treatments. Diaprost... Read More
